Reality Check

MMIT Reality Check on Chemotherapy-Induced Nausea and Vomiting (June 2021)

According to our recent payer coverage analysis for chemotherapy-induced nausea and vomiting (CINV) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. ...
0 Comments

MMIT Reality Check on Hereditary Angioedema (June 2021)

According to our recent payer coverage analysis for hereditary angioedema (HAE) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make sense...
0 Comments

MMIT Reality Check on Non-Small Cell Lung Cancer BRAF+ (May 2021)

According to our recent payer coverage analysis for non-small cell lung cancer BRAF+ treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make ...
0 Comments

MMIT Reality Check on Cervical Cancer (May 2021)

According to our recent payer coverage analysis for cervical cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make sense of this new...
0 Comments

MMIT Reality Check on Atopic Dermatitis (May 2021)

According to our recent payer coverage analysis for atopic dermatitis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make sense of this n...
0 Comments

MMIT Reality Check on Narcolepsy (May 2021)

According to our recent payer coverage analysis for narcolepsy treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make sense of this new rese...
0 Comments

MMIT Reality Check on Anemia — Chronic Kidney Disease (Apr 2021)

According to our recent payer coverage analysis for anemia treatments due to chronic kidney disease, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help m...
0 Comments

MMIT Reality Check on Hemophilia B (Factor IX) (Apr 2021)

According to our recent payer coverage analysis for hemophilia B (factor IX) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make sense of...
0 Comments

MMIT Reality Check on Growth Hormone Deficiency (Apr 2021)

According to our recent payer coverage analysis for growth hormone deficiency (GHD) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make s...
0 Comments

MMIT Reality Check on Acute Myeloid Leukemia (Apr 2021)

According to our recent payer coverage analysis for acute myeloid leukemia treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make sense of t...
0 Comments